From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations -- T1D and/or T2D -- are they best suited? How are these agents titrated?

From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations -- T1D and/or T2D -- are they best suited? How are these agents titrated?

From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations — T1D and/or T2D — are they best suited? How are these agents titrated?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium